Año 2025 / Volumen 117 / Número 2
Carta
Mesalamine induced hepatotoxicity. Is mesalamine safe?

108-110

DOI: 10.17235/reed.2024.10131/2023

Javier Pérez-Valenzuela, Lorena Castro Solari, Rodrigo Quera, Luis Contreras,

Resumen
Mesalamine is a medication used widely in the treatment of patients with inflammatory bowel disease. Although mesalamine is considered safe, hepatotoxicity has been reported with an incidence of 0-4%. We present the clinical picture of a patient with hepatotoxicity due to mesalamine. A 79-year-old woman in the context of chronic diarrhea, a left-sided ulcerative colitis diagnosis was made, and treatment was initiated with oral mesalamine 4 g per day, and mesalamine suppositories. Before starting treatment, she had normal liver test results. After three months, she presented with headache, fatigue, and intermittent low fever. Her laboratory tests showed a liver profile with a cholestatic pattern, and elevation of inflammatory parameters. Mesalamine was suspended, and an extensive study was performed. Cholangioresonance reported intra and extrahepatic bile duct dilation without obstruction, and thickening of the intrahepatic bile duct. She progressed with worsening of the liver profile without signs of liver failure. A liver biopsy was performed, which showed chronic non-suppurative cholangitis with granulomas and focal concentric fibrosis related to medium-caliber bile ducts, and IgG4 stain was negative.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep [Internet]. 2020 Sep 15;22(9):47.
2. Feagan BG, Chande N, MacDonald JK. Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflamm Bowel Dis [Internet]. 2013 Jun;19(9):1.
3. Bessone F, Hernández N, Mendizábal M, Sánchez A, Paraná R, Arrese M, et al. Cuando la creación de un consorcio proporciona respuestas útiles: experiencia de la Latin American DILI network (LATINDILIN). Clin Liver Dis [Internet]. 2019 May 29;13(S1):S17–23.
4. Sehgal P, Colombel J ‐F., Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther [Internet]. 2018 Jun 3;47(12):1597–609.
5. Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliar manifestations in inflammatory bowel disease: A practical approach. World J Hepatol [Internet]. 2022 Feb 27;14(2):319–37.
Instrucciones para citar
Pérez-Valenzuela J, Castro Solari L, Quera R, Contreras L. Mesalamine induced hepatotoxicity. Is mesalamine safe?. 10131/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1355 veces.
Este artículo ha sido descargado 86 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 01/12/2023

Aceptado: 14/12/2023

Prepublicado: 11/01/2024

Publicado: 05/02/2025

Tiempo de prepublicación: 41 días

Tiempo de edición del artículo: 432 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas